Subtle cognitive decline and biomarker staging in preclinical Alzheimer’s disease
Manuscript Number:
15-0128R1
Author(s):
Mark W. Bondi, Lisa Delano-Wood, Emily C. Edmonds, Douglas Galasko, David P. Salmon
Disclosures
Mark W. Bondi
Nothing to Disclose
Lisa Delano-Wood
Nothing to Disclose
Emily C. Edmonds
Nothing to Disclose
Douglas Galasko
Consulting Fees:
Serve on Data Safety Monitoring Boards for clinical trials for Balance Pharmaceuticals, Inc; Astra-Zeneca, Inc; Neotope Pharmaceuticals.
Consultant for TransTech Pharmaceuticals, Inc